This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Pen Injectors - Devices, Drugs, Combination Products

NEW YORK, March 19, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pen Injectors - Devices, Drugs, Combination Products http://www.reportlinker.com/p0761238/Pen-Injectors---Devices-Drugs-Combination-Products.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_TechnologyUser-friendly designs and the availability of an increasing number of drugs in pre-filled disposable cartridges and syringes are propelling the growth of injector pens at the expense of other drug delivery methods such as traditional syringes. Advances in synthetic materials and concurrent development partnerships between pen designers and drug developers are important factors in the growth of this segment. With product evaluations, industry data and forecasts, pen injector company profiles, and detailed analysis of design and economic factors, this report has been organized and written to provide pharmaceutical professionals, drug delivery market participants, and healthcare organizations with all of the information necessary to understand the growing importance of pen injectors on drug development and delivery.

Highlights• Provides detailed analysis of pen injector market segments, market dynamics and market demographics• Analyzes therapeutic demand drivers and evaluates commercial pen injector products in eleven major therapeutic segments• Analyzes design factors, material selection issues, technologies and market development issues• Charts product data, market share, and forecasts to 2018• Profiles injectable drug and device participants, their pen injector product development activities, business strategies, and corporate alliances and affiliations

Summary of Contents Executive Summary Injectable Drug Sector Market DynamicsThe Injectable Drug EcosystemDrug Classes, Indications and DemandWhat's Driving the Growth in Pen InjectorsBiological Drugs ProliferatingGrowth of Self-AdministrationShifting Demographics Device Design InnovationCompetitive LandscapeRisk Factors

Pen Injector Design Selection FactorsStandardized Pen PlatformsCustom Pen DesignsReusable PensPrefilled Pen CartridgesDisposable PensDual Chamber PensVariable vs Fixed Dosing AutoinjectorsReusable AutoinjectorsDisposable Autoinjectors

Important Pen-Delivered Drug ClassesAnticholonergicsDopamine ReceptorsHematopoieticsHuman Growth HormoneImmune ModulatorsInsulins and AntihyperglycemicsParathyroid HormoneReproductive HormonesSerotonin AntagonistsSympathomimetics

Pen Injectors - Therapeutic Sector Assessment AnemiaInflammatory Autoimmune DiseasesDiabetesEmergency MedicineHepatitisHormone ReplacementMultiple SclerosisOsteoporosisReproductive HealthOther Commercial Pen Markets & Products

Market FactorsRegulatory ConsiderationsPatient Preferences and ComplianceManaged Care InitiativesPrivate Labeling

Pen Injectors - Company Profiles

To order this report: Drug_Delivery_Technology Industry: Pen Injectors - Devices, Drugs, Combination Products

__________________________Contact Clare: clare@reportlinker.comUS:(339) 368 6001Intl:+1 339 368 6001

 

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,086.63 -26.91 -0.16%
S&P 500 1,987.01 +3.48 0.18%
NASDAQ 4,473.6970 +17.6810 0.40%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs